Medicare's GLP-1 Bridge program launched on July 1, 2026, making three weight-loss GLP-1 therapies — Wegovy, Zepbound (KwikPen only), and Foundayo (tablet) — available to eligible Part D beneficiaries at a flat $50 monthly copay, outside the standard Part D benefit structure.

CMS announced the model in December 2025 as a voluntary framework sitting alongside — not inside — the standard Part D benefit. Beneficiaries must be enrolled in an eligible Part D plan type and using the medication specifically to reduce excess body weight. That eligibility gate matters: GLP-1s prescribed for type 2 diabetes management are handled through existing Part D pathways; the Bridge is explicitly scoped to the obesity indication.

The program's timeline has already been extended. CMS confirmed on June 22, 2026 that the Bridge runs through December 31, 2027 — an 18-month window that gives the agency time to collect utilization and outcomes data before any decision on permanent integration into the standard benefit.

Structure and Cost-Sharing Mechanics

The $50 fixed copay is the defining feature. Standard Part D cost-sharing for high-list-price specialty drugs — Wegovy's list price is well north of $1,000 per month — would expose beneficiaries to substantially higher out-of-pocket exposure under normal formulary tiers, even post-IRA redesign with its $2,000 annual cap. The Bridge sidesteps that by operating outside the standard benefit, effectively functioning as a parallel coverage lane with a capped, predictable patient cost.

For Part D plan sponsors participating in the model, the financial mechanics are distinct from standard benefit administration. Because the Bridge sits outside the standard Part D benefit, standard reinsurance and risk corridor arrangements do not apply in the same way, and plan sponsors need to account for Bridge claims separately. CMS's guidance to Part D plans and its provider-facing information both underscore the voluntary nature of plan participation — no plan is compelled to join, which creates a patchwork coverage landscape that beneficiaries and prescribers will need to navigate.

Medicaid Context and the Broader Spending Trajectory

The Medicaid picture provides useful contrast. An HHS OIG report published December 2024 found that Medicaid gross spending on ten selected diabetes drugs and two weight-loss drugs exceeded $9 billion in 2023 — a 540% increase from 2019. Most state Medicaid programs cover GLP-1s for diabetes management, but most do not cover them for weight loss. The spending surge has arrived even without broad obesity coverage at the Medicaid level; a policy shift there would amplify the numbers substantially.

Medicare Part D, by contrast, was explicitly prohibited from covering weight-loss drugs under pre-IRA statute. The Inflation Reduction Act opened the door legislatively, and the Bridge is CMS's initial operational response. The $50 copay design is calibrated to maximize uptake while keeping patient cost visible — the agency is clearly running this as a real-world evidence exercise as much as a coverage expansion.

What This Means for Plan Sponsors, PBMs, and Manufacturers

For Part D plan sponsors, the immediate question is formulary positioning and network adequacy for the three covered products. Wegovy and Zepbound are already well-established commercially; Foundayo's tablet formulation adds an administration-route option that may matter for adherence in older populations. PBMs negotiating rebates within the Bridge framework are operating in a CMS-structured model where list price, net price, and the $50 consumer cost are all on the table simultaneously.

Manufacturer incentives are significant. Coverage by Medicare — even through a temporary bridge model — establishes a reimbursement precedent and adds the 67-million-beneficiary Medicare population to the addressable market for the obesity indication. Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have been expanding manufacturing capacity in anticipation of precisely this kind of coverage broadening. Foundayo's inclusion places a third product — presumably from a different manufacturer — in a preferred position from day one of the program.

The 18-month duration is short enough that CMS retains maximum policy flexibility. If utilization overshoots projections or outcomes data disappoints, the agency can restructure or close the program by end-2027 without having embedded the benefit permanently. That optionality is deliberate, and market participants should price it accordingly.